Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.
Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kubáčková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Šikić BI. Vrdoljak E, et al. Among authors: beslija s. Oncologist. 2016 Oct;21(10):1183-1190. doi: 10.1634/theoncologist.2016-0137. Epub 2016 Jul 8. Oncologist. 2016. PMID: 27401890 Free PMC article.
Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.
Vrdoljak E, Bodoky G, Jassem J, Popescu R, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kopečková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Sikic B. Vrdoljak E, et al. Among authors: beslija s. Oncologist. 2019 Jan;24(1):e30-e37. doi: 10.1634/theoncologist.2018-0093. Epub 2018 Sep 4. Oncologist. 2019. PMID: 30181313 Free PMC article.
Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers.
Miletić D, Kraljević M, Sokolović E, Soče M, Milović-Kovačević M, Bobić S, Cerić T, Pleština S, Bešlija S, Marijanović I. Miletić D, et al. Among authors: beslija s. Med Sci Monit. 2023 Jun 2;29:e940356. doi: 10.12659/MSM.940356. Med Sci Monit. 2023. PMID: 37264567 Free PMC article.
Third consensus on medical treatment of metastatic breast cancer.
Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H; Central European Cooperative Oncology Group (CECOG). Beslija S, et al. Ann Oncol. 2009 Nov;20(11):1771-85. doi: 10.1093/annonc/mdp261. Epub 2009 Jul 16. Ann Oncol. 2009. PMID: 19608616 Free article. Review.
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C. Brodowicz T, et al. Among authors: beslija s. Br J Cancer. 2014 Nov 25;111(11):2051-7. doi: 10.1038/bjc.2014.504. Epub 2014 Sep 30. Br J Cancer. 2014. PMID: 25268370 Free PMC article. Clinical Trial.
2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.
Bešlija S, Gojković Z, Cerić T, Mekić Abazović A, Marijanović I, Vranić S, Mustedanagić-Mujanović J, Skenderi F, Rakita I, Guzijan A, Koprić D, Humačkić A, Trokić D, Alidžanović J, Efendić A, Šišić I, Drljević H, Bešlagić V, Babić B, Pašić A, Ramić A, Mikić D, Guzin Z, Karan D, Buhovac T, Miletić D, Šečić S, Đozić Šahmić A, Mujbegović L, Kubura A, Burina M, Lalović N, Dukić N, Vladičić Mašić J, Ćuk M, Stanušić R. Bešlija S, et al. Bosn J Basic Med Sci. 2021 Apr 1;21(2):120-135. doi: 10.17305/bjbms.2020.4846. Bosn J Basic Med Sci. 2021. PMID: 32415816 Free PMC article.
43 results